Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Basic): 2020-2025

Historic EPS (Basic) for Silence Therapeutics (SLN) over the last 4 years, with Sep 2025 value amounting to -$0.15.

  • Silence Therapeutics' EPS (Basic) rose 40.00% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.15, marking a year-over-year increase of 40.00%. This contributed to the annual value of -$0.33 for FY2024, which is 32.65% up from last year.
  • Silence Therapeutics' EPS (Basic) amounted to -$0.15 in Q3 2025, which was up 21.05% from -$0.19 recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' EPS (Basic) peaked at $0.09 during Q4 2024, and registered a low of -$0.25 during Q3 2024.
  • Its 3-year average for EPS (Basic) is -$0.12, with a median of -$0.15 in 2025.
  • As far as peak fluctuations go, Silence Therapeutics' EPS (Basic) surged by 166.92% in 2024, and later tumbled by 900.00% in 2025.
  • MRQ analysis of 4 years shows Silence Therapeutics' EPS (Basic) stood at -$0.16 in 2022, then grew by 13.69% to -$0.13 in 2023, then skyrocketed by 166.92% to $0.09 in 2024, then crashed by 266.67% to -$0.15 in 2025.
  • Its last three reported values are -$0.15 in Q3 2025, -$0.19 for Q2 2025, and -$0.20 during Q1 2025.